April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Proton Beam Therapy of Iris Melanoma
Author Affiliations & Notes
  • G. D. Willerding
    Charite Universitaetsmedizin, Berlin, Germany
  • D. Cordini
    Charite Universitaetsmedizin, Berlin, Germany
  • L. Moser
    Charite Universitaetsmedizin, Berlin, Germany
  • N. E. Bechrakis
    Augenklinik, Universitaet Innsbruck, Innsbruck, Austria
  • M. H. Foerster
    Charite Universitaetsmedizin, Berlin, Germany
  • Footnotes
    Commercial Relationships  G.D. Willerding, None; D. Cordini, None; L. Moser, None; N.E. Bechrakis, None; M.H. Foerster, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5155. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. D. Willerding, D. Cordini, L. Moser, N. E. Bechrakis, M. H. Foerster; Proton Beam Therapy of Iris Melanoma. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5155.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To report the results of proton beam therapy of iris melanoma.

Methods: : Retrospective, interventional, consecutive, single-institution case series.

Results: : 54 patients were treated between Oct. 1998 and Nov. 2008 with a dose of 4x15 CGE proton beam. 51 Patients received whole-iris irradiation due to presumed diffuse tumor spread. Mean patient age was 54 years. Mean follow up is 39 months. Tumor control was achieved in 53 cases. Complications included secondary enucleation in one case, cataract in any case with a minimum follow up of 12 months and secondary glaucoma in 34 patients.

Conclusions: : Proton beam therapy offers a high rate of tumor control in this subset of patients. Cataract and glaucoma appear to be very common after treatment.

Keywords: iris • melanoma • radiation therapy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.